We are pleased to announce the expansion of the NIGMS Repository Induced Pluripotent Stem Cell (iPSC) collection with several new disease-specific and isogenic control cell lines. iPSCs hold incredible value for scientific research across many disciplines and can accelerate progress toward cures for many diseases.
The NIGMS Repository houses iPSCs derived from apparently healthy individuals, patient-derived disease-specific iPSCs, and isogenic controls. These additions further strengthen the existing collection, providing researchers with enhanced tools for disease modeling, cell differentiation studies, target validation, drug discovery, functional genomics, and experimental controls.
Established in 1972 at the Coriell Institute for Medical Research, the NIGMS Repository contains more than 11,900 cell lines, primarily fibroblasts and transformed lymphoblasts, and more than 6,200 DNA samples. Currently, the NIGMS HGCR catalog also contains over 180 iPSC lines. Repository samples represent a variety of disease states, chromosomal abnormalities, apparently healthy individuals, and many distinct human populations. These samples comprise over 1,100 different OMIM diagnoses and have been referenced in over 8,100scientific publications, underscoring their broad research value.
Coriell is committed to providing the scientific community with high-quality and well-characterized cell cultures — including induced pluripotent stem cells — and DNA/RNA preparations, annotated with rich phenotypic and genetic data, to support research applications. Our laboratories operate under the most stringent ISO 9001:2015-certified standard operating procedures, including performance of quality control testing and assessment of pluripotency.
Interested in learning more? Click here to learn more.
For the past 72 years, in pursuit of preventing and curing diseases, Coriell scientists have conducted groundbreaking research in infectious diseases, genetic diseases, cancer, aging and personalized medicine. Coriell has also pioneered the generation of research-accelerating biomaterials through establishing and curating key biobanks that now contain some of the world’s most extensive collection of cell lines, DNA, and other biomaterials gathered and distributed for use by the international research community. Coriell holds one of the first two official cell banks recognized by the National Institutes of Health (NIH) in 1960. Coriell currently hosts biobanks for the following NIH institutes: NIGMS, NINDS, NHGRI, NEI, and NIA. In addition to its biobanks, Coriell researchers currently study aging, cancer, stem cells, epigenomics, pharmacogenomics and many more topics. Many projects, such as the longstanding Camden Opioid Research Initiative (CORI - funded by the state of NJ) and the newly launched Camden Cancer Research Center (CCRC), focus more broadly on the historically underserved city of Camden and Southern New Jersey.
